BioSpace News Archive

Terns Pharmaceuticals, Inc. announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis programs within the Company’s portfolio were accepted for presentation at The International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom.

Iovance Biotherapeutics, Inc., a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announced that senior leadership plans to present at the following conferences in June.

Aquestive Therapeutics, Inc. announced that it has closed its previously announced registered direct offering with a single healthcare-focused institutional investor and certain of the Company’s executives, to purchase 8,850,000 shares of its common stock and warrants to purchase up to an aggregate of 8,850,000 shares of common stock at a purchase price per share of $0.96 for the institutional investor and $1.09 for the Company’s executives for gross proceeds of approximately $8.5 million.

Neurocrine Biosciences, Inc. will present at the Goldman Sachs 43rd Annual Global Healthcare Conference at 10:40 a.m. Pacific Time on Wednesday, June 15, 2022 in Rancho Palos Verdes, CA.

Vertex Pharmaceuticals Incorporated announced that the company will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022 at 1:20 p.m. PT.

CureVac N.V. announced its acquisition of Frame Cancer Therapeutics, a private company focused on advanced genomics and bioinformatics to identify both unique and shared neoantigens across different cancer types.

SINOVAC Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that it received the World Health Organization prequalification for its Poliomyelitis Vaccine on June 2, 2022.

Includes oral presentation on Prospera test’s two-threshold algorithm, showing the combination of donor quantity and donor fraction outperforms donor fraction alone.

Better Therapeutics, Inc . (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S. Patent and Trade Office (USPTO) has granted their first patent, granting twenty years of exclusivity for a number of key features core to the company’s digital therapeutics platform.

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the company’s clinical stage LSD1 inhibitor iadademstat for the treatment of patients with small cell lung cancer (SCLC).